At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
SL-172154drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L) Administered Intravenously in Subjects With Ovarian Cancer
In Brief
A Phase 1 clinical trial evaluating SL-172154 for Ovarian Cancer and 2 related conditions. Completed, enrolled 27 participants across 6 sites.
Detailed Summary
This is a Phase 1 first in human, open label, multi-center, dose escalation study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-172154 in subjects with ovarian cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJun 2020
Primary CompletionFeb 2023
TodayJul 2026
First PostedMay 28, 2020
Enrollment StartJun 29, 2020
Primary CompletionFeb 2, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.1 years ago
Interventions
SL-172154drug
The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.